Primary esophageal melanoma: report of a case

Introduction: Primary malignant melanoma of the esophagus is a rare tumor representing only 0.1-0.2% of esophageal malignancies. The goal of the study was to report on the management of a new case diagnosed and treated in our site. Case report: A 67-year-old patient presented with dysphagia to solid...

Full description

Bibliographic Details
Main Authors: Laura Granel-Villach, María Amparo Moya-Sanz, Vicente Javier Escrig-Sos, Carlos Fortea-Sanchís, Carmen Martínez-Lahuerta, Nuria Tornador-Gaya, José Luis Salvador-Sanchís
Format: Article
Language:English
Published: Aran Ediciones
Series:Revista Espanola de Enfermedades Digestivas
Subjects:
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082016001000015&lng=en&tlng=en
Description
Summary:Introduction: Primary malignant melanoma of the esophagus is a rare tumor representing only 0.1-0.2% of esophageal malignancies. The goal of the study was to report on the management of a new case diagnosed and treated in our site. Case report: A 67-year-old patient presented with dysphagia to solids with no other remarkable history or associated skin lesions. He underwent gastroscopy, which revealed a polypoid mass suggestive of neoplasm in the distal third of the esophagus. Biopsy indicated melanoma with positive immunohistochemical markers S100 and HMB45, and negative cytokeratins and CEA. Computerized tomography (CT) and positron-emission tomography (PET) scans showed no local infiltration or distant metastases. An Ivor-Lewis esophagectomy procedure was performed with regional lymphadenectomy. Postoperative stay lasted for three weeks, and no remarkable postsurgical complications arose. The pathological study of the specimen confirmed the diagnosis of primary esophageal melanoma. Discussion: Primary malignant melanoma of the esophagus has an unfortunate prognosis as it is an aggressive tumor usually diagnosed at an advanced stage, with local invasion and metastatic disease. Currently, surgery is the treatment of choice, with the remaining adjuvant therapies obtaining limited results.
ISSN:1130-0108